MASLD/MASH Learning Center
Journal Club: Review of Focused Recommendations for the Management of MASLD
September 2026
Thank you to Madrigal for your support on this Journal Club Review video module. This journal club review explores the 2025 focused recommendations for the management of metabolic dysfunction–associated steatohepatitis (MASH) developed by advanced practice providers (APPs) across the United States and published in the Journal of Clinical Gastroenterology. Brian Lam, PA-C, reviews the evolving role of APPs in MASH care, key epidemiology insights, risk stratification using non-invasive tests, and practical guidance on identifying and treating at-risk patients with F2–F3 fibrosis. The discussion highlights real-world use of ELF, FibroScan, and FIB-4, an overview of resmetirom therapy, monitoring strategies, and a look ahead at emerging therapies shaping the future of MASH management. Please visit GHAPP.org, the GHAPP Digital Hub, or the GHAPP ACE 2.0 app for additional resources.
Watch Now
Medication Review: Resmetirom: Thyroid Hormone Receptor-β Agonism in MASH Treatment
September 2026
Thank you to Madrigal for your support of this Medication Review Video Module. In this medication review module, Michelle Barnett, PA-C, provides an in-depth overview of resmetirom, the first FDA-approved liver-directed thyroid hormone receptor beta (THR-β) agonist for adults with non-cirrhotic metabolic dysfunction–associated steatohepatitis (MASH) and moderate to advanced fibrosis (F2–F3). The discussion reviews MASH risk factors, resmetirom’s mechanism of action, dosing considerations, and key findings from the phase 3 MAESTRO-NASH trial, including improvements in liver histology and lipid parameters. Designed for APPs and clinicians, this concise review highlights how resmetirom fits into contemporary MASH management alongside lifestyle interventions such as diet and exercise. Please visit GHAPP.org, the GHAPP Digital Hub, or the GHAPP ACE 2.0 app for additional resources.
Watch Now
Medication Review: Resmetirom: Core Efficacy Data and Patient Selection Considerations
September 2026
Thank you to Madrigal for your support of this Medication Review Video Module. Discover how Resmetirom is reshaping the treatment landscape for metabolic dysfunction–associated steatohepatitis (MASH) in this expert-led medication review with HoChong Gilles, DNP. This short medication review breaks down the therapy’s mechanism of action, pivotal MAESTRO-NASH trial data, fibrosis and steatohepatitis endpoints, ideal patient selection (F2–F3 disease), and key safety considerations. Learn how this first-in-class THR-β agonist delivers meaningful improvements in fibrosis and steatohepatitis without worsening disease, and why 2024 marked a turning point in MASH care. Perfect for APPs and clinicians looking to stay ahead in the rapidly evolving world of liver disease management. Please visit GHAPP.org, the GHAPP Digital Hub, or the GHAPP ACE 2.0 app for additional resources.
Watch Now
FAQ: What is the Relevance of Assessing Alcohol Consumption in Patients With MASH?
September 2026
Thank you to Madrigal for their support on this FAQ Video Module. In this FAQ video, Alison Moe, PA-C, discusses how alcohol consumption impacts the evaluation and progression of metabolic dysfunction–associated steatohepatitis (MASH) and why accurate assessment is critical in clinical practice. The discussion reviews the synergistic effects of alcohol and metabolic liver disease on fibrosis progression, explains current alcohol intake thresholds associated with increased risk, and outlines how biomarkers such as phosphatidylethanol (PEth) can provide objective insight into recent alcohol use. Designed for APPs and clinicians, this practical overview highlights how to differentiate MASH, alcohol-related liver disease (ALD), and MetALD to ensure accurate diagnosis, documentation, and treatment decisions.
Watch Now
FAQ: How Do You Balance Systemic and Liver Directed Therapies in Patients With MASH?
September 2026
Thank you to Madrigal for their support on this FAQ Video Module. In this FAQ video, Allysa Saggese, NP, reviews how clinicians can balance systemic and liver-directed therapies in the treatment of metabolic dysfunction–associated steatohepatitis (MASH) and shares insights on the evolving role of combination therapy. The discussion explores current guideline-aligned options, including GLP-1–based systemic therapies and liver-directed agents, and emphasizes individualized treatment decisions based on fibrosis stage, metabolic comorbidities, patient preferences, and access considerations. Designed for APPs and clinicians, this overview highlights why multimodal therapy—alongside lifestyle interventions like diet and exercise—is likely the future of MASH management. Please visit GHAPP.org, the GHAPP Digital Hub, or the GHAPP ACE 2.0 app for additional resources.
Watch Now
FAQ: What Role Do NITs Play in Risk Stratification & Patient Selection—& Balancing Patient History?
September 2026
Thank you to Madrigal for your support on this FAQ Video Module. In this short FAQ video module, Patrick Horne, President of GHAPP and a nurse practitioner at the University of Florida, discusses the critical role of noninvasive tests (NITs) in risk stratification and patient selection for patients with metabolic dysfunction–associated steatohepatitis (MASH). He explains how serum biomarkers and imaging help establish baseline fibrosis, clarify disease severity, and guide clinical decision-making in a condition with variable and non-linear progression. This overview emphasizes the importance of integrating NITs with a thorough patient history and physical exam to better understand fibrosis stage and optimize patient evaluation. Visit the GHAPP Digital Hub or GHAPP ACE 2.0 app for more gastroenterology and hepatology education.
Watch Now
FAQ: What Are The Functional And Prognostic Differences Between Fibrosis F3 And F4 Patients?
September 2026
Thank you to Madrigal for your support on this FAQ Video Module. In this episode, Christina Hanson, NP, breaks down the key functional and prognostic differences between fibrosis stage F3 and F4, explaining how liver architecture, portal hypertension, and risk of decompensation shape patient outcomes. Learn how staging impacts mortality risk in MASLD/MASH, why accurate identification of advanced fibrosis is critical, and how management strategies differ for patients with severe fibrosis versus cirrhosis. Christina reviews how clinicians can intervene early, slow progression, and monitor for complications such as variceal bleeding, ascites, and hepatic encephalopathy, while emphasizing the importance of addressing underlying liver disease to improve long-term survival. Please visit GHAPP.org, the GHAPP Digital Hub, or the GHAPP ACE 2.0 app for additional resources.
Watch Now
New Treatment Options for MASH
August 2026
In this educational overview, Summer Collier, DNP, RN, FNP-BC at UC San Diego Health, discusses semaglutide as an FDA-approved treatment option for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH, and moderate-to-advanced liver fibrosis. She explains how semaglutide may support both MASH treatment and broader metabolic goals, particularly for patients with obesity, type 2 diabetes, hypertension, high cholesterol, or a need for weight loss. The discussion compares semaglutide and resmetirom, highlighting how metabolic dysfunction, weight-loss goals, fibrosis risk, and the need for liver-directed therapy can guide individualized treatment selection. Collier also shares her stepwise approach to MASH pharmacotherapy, including optimizing one medication before considering combination therapy and when resmetirom may be added for patients who remain at risk despite being stable on semaglutide or another GLP-1 therapy. Viewers will gain practical insights into integrating medication with nutrition, physical activity, weight management, and shared decision-making as the MASH treatment landscape continues to evolve.
Watch Now
Lessons Learned in 2025 MASLD Care
January 2026
Patrick Horne, NP shares real-world clinical insights as we head into 2026, reflecting on a pivotal year in the management of MASLD and MASH. With two approved therapies now available, he discusses growing patient receptiveness, increasing provider confidence, and early improvements seen on FibroScan and elastography after sustained treatment. The update also highlights the impact of recently updated American Association for the Study of Liver Diseases guidelines, the importance of fibrosis staging, and ongoing efforts to educate primary care and GI colleagues on practical disease management. This brief reflection underscores meaningful progress in MASLD and MASH care and looks ahead to continued advances in 2026.
Watch Now
Live From GHAPP National: Drug Induced Liver Injury
November 2025
In this high-yield session, Kate Lee-Young, DNP from Johns Hopkins, provides a clear and practical overview of drug-induced liver injury (DILI)—the most common cause of acute liver failure in the U.S. She reviews how DILI happens, common offending agents (including acetaminophen, antibiotics, anti-tubercular drugs, and herbal supplements like ashwagandha), key clinical patterns of injury, and how to diagnose DILI using history, labs, imaging, and R-value classification. Viewers will learn when to suspect DILI, how to rule out other liver diseases, when biopsy is useful, and essential steps in management including drug discontinuation, supportive care, NAC use, and prevention strategies. A concise, evidence-based guide for hepatology APPs and clinicians navigating suspected drug-related liver injury.
Watch Now
Live From GHAPP National: MASH Basics
November 2025
In this session, Tessa Janovsky, PA from Arizona Liver Health, provides a clear, practical overview of the basics of MASH and MASLD, including the updated 2023 steatotic liver disease nomenclature, global prevalence trends, and why MASH is a progressive metabolic liver disease that requires early identification. She reviews high-risk populations, the role of primary care and specialty providers, how to use FIB-4 and non-invasive tests to assess fibrosis, and the importance of recognizing rapid progressors. Using a real clinical case, she highlights how to evaluate patients, rule out other etiologies, and optimize metabolic health—including when to consider pharmacotherapy. A concise, clinic-ready primer for clinicians managing MASLD and MASH.
Watch Now
Live From GHAPP National: Abnormal Liver Chemistry Workup
November 2025
In this session, Jeremy Davis, ACNP from Shreveport, Louisiana, breaks down a practical, step-by-step approach to evaluating abnormal liver chemistries. Using a real patient case, he reviews how to interpret ALT, AST, ALP, bilirubin, MCV, and GGT patterns; when to suspect hepatocellular, cholestatic, or mixed injury; and how to build an efficient differential using history, medications, alcohol assessment, and key labs (viral hepatitis panel, autoimmune markers, iron studies, Wilson disease testing, alpha-1 antitrypsin phenotype). He also highlights the role of ultrasound, MRCP, non-invasive fibrosis tests (FIB-4, ELF, VCTE), and when biopsy is needed. A practical, clinic-ready guide for APPs and clinicians assessing elevated liver enzymes and differentiating MASLD, alcohol-related disease, DILI, and other common etiologies.
Watch Now